Artificial intelligence (AI) is shifting from improving processes ... treatments that target each patient's unique genes. But this revolution will create clear winners and losers.

Morgan Stanley has finally conceded that Palantir Technologies is not a stock to sell, but its analysts aren’t quite ready to ...